Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy

Lancet
K J OsterzielR Dietz

Abstract

Some studies have suggested that treatment with recombinant human growth hormone (rhGH) increases left-ventricular mass and improves haemodynamic and functional status in patients with heart failure due to dilated cardiomyopathy. We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy. 50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks. The primary endpoints were the effects on left-ventricular mass and systolic wall stress. The secondary endpoints were the effects on left-ventricular size and function. Data were analysed by intention to treat. Patients in the rhGH group had an increase in left-ventricular mass compared with those in the placebo group (27%, p=0.0001). There was no significant difference in left-ventricular systolic wall stress, mean blood pressure, or systemic vascular resistance between the two groups. New York Heart Association functional class, left-ventricular ejection fraction, and distance on the 6 min walking test were unchanged. The change in serum insulin-like growth factor (IGF)-I concentrations (rhGH 77 ng/mL; placebo -19 ng/mL, GH vs placebo p=...Continue Reading

Associated Clinical Trials

References

Nov 1, 1991·Acta Endocrinologica·J O JørgensenJ S Christiansen
May 1, 1989·Journal of the American College of Cardiology·P T BuserC B Higgins
Jul 1, 1989·The Journal of Pediatrics·D L DonaldsonW V Moore
Feb 1, 1989·The Journal of Clinical Endocrinology and Metabolism·A C CelnikerB M Sherman
Nov 1, 1988·Radiology·J KatzR M Peshock
Nov 1, 1995·The Journal of Clinical Investigation·W ChengP Anversa
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·M BuerkeA M Lefer
Jun 1, 1993·The Journal of Clinical Endocrinology and Metabolism·W F BlumM B Ranke
Oct 1, 1994·The Journal of Clinical Investigation·R A GottliebR L Engler
Dec 8, 1994·The New England Journal of Medicine·G W Dec, V Fuster
May 1, 1994·European Journal of Endocrinology·S A BeshyahD G Johnston
Mar 28, 1996·The New England Journal of Medicine·S FazioL Saccà
Mar 1, 1996·American Heart Journal·A GiustinaO Alfieri
May 1, 1996·The Journal of Pediatrics·R G Rosenfeld, S E Gargosky

❮ Previous
Next ❯

Citations

Dec 13, 2000·Statistics in Medicine·G D PinnaM Sanarico
Mar 10, 2001·Journal of Magnetic Resonance Imaging : JMRI·O StrohmM G Friedrich
Dec 8, 2005·Current Heart Failure Reports·Yoshihiro J AkashiStefan D Anker
Aug 9, 2013·Current Heart Failure Reports·Vincent Pureza, Viorel G Florea
May 6, 2004·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·K G MatthewsJ J Bass
Apr 6, 2005·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·M Bohlooly-YE Omerovic
May 8, 2004·Molecular and Cellular Endocrinology·Ryo ImanishiKatsusuke Yano
Jun 25, 2002·The Annals of Thoracic Surgery·Tsung-Po TsaiFong-Lin Chen
Dec 13, 2001·European Journal of Pharmacology·J T MacAndrewS C Black
Oct 21, 1999·European Journal of Pharmacology·G BisiE Ghigo
Jul 2, 2003·Regulatory Peptides·Noritoshi Nagaya, Kenji Kangawa
Aug 7, 2002·International Journal of Cardiology·Stefan D Anker, Rakesh Sharma
Aug 7, 2002·International Journal of Cardiology·Marijke BrinkPatrick Delafontaine
Jun 25, 2003·Journal of the American College of Cardiology·Antonio CittadiniLuigi Saccà
Dec 15, 2000·Progress in Pediatric Cardiology·A M MoranJ W Newburger
Sep 13, 2000·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·O Mehls, S Haas
Aug 23, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Elmir OmerovicJörgen Isgaard
Aug 14, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Anders Juul
Apr 12, 2003·Current Opinion in Pharmacology·Noritoshi Nagaya, Kenji Kangawa
Nov 1, 2005·Nature Clinical Practice. Cardiovascular Medicine·Dipan J ShahRaymond J Kim
Mar 22, 2000·Journal of Endocrinological Investigation·A BensoE Ghigo
Sep 1, 1999·Clinical Endocrinology·R C Jenkins, R J Ross
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Rosemeire M Kanashiro-TakeuchiJoshua M Hare
Feb 9, 2012·Cardiology in Review·Christopher R PalmeiroIrene A Weiss
Mar 13, 2009·Clinical and Experimental Pharmacology & Physiology·Vanessa O MoreiraAna V B Castro
Jun 27, 2000·Australian and New Zealand Journal of Medicine·L A Bach
Feb 1, 2002·Congestive Heart Failure·Rakesh Sharma, Stefan D Anker
Jan 5, 2002·Journal of Cardiac Surgery·A PerrotK J Osterziel
May 6, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Song-Jung KimGeorge J Crystal
Nov 28, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Yosuke KatoMitsuhiro Yokota
Sep 22, 2000·Pharmacotherapy·T M NgM A Munger
Apr 7, 2006·Drugs·Noritoshi Nagaya, Kenji Kangawa
Jun 29, 2005·Treatments in Endocrinology·Annamaria ColaoGaetano Lombardi
Feb 19, 2010·The American Journal of Clinical Nutrition·Norleena P GullettThomas R Ziegler
Nov 28, 2002·European Journal of Heart Failure·Peter J PughKevin S Channer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.